Experimental Hematology
Volume 30, Issue 10 , Pages 1124-1131 , October 2002

Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo

  • Hayley S Ramshaw

      Affiliations

    • Cytokine Receptor Laboratory, Division of Human Immunology, IMVS, Adelaide, South Australia
    • ,
  • Peter G Bardy

      Affiliations

    • Departments of Haematology and Transplant Services, Australian Redcross Blood Service South Australia and Division of Haematology, IMVS, Adelaide, South Australia
    • ,
  • Melissa A Lee

      Affiliations

    • Cytokine Receptor Laboratory, Division of Human Immunology, IMVS, Adelaide, South Australia
    • ,
  • Angel F Lopez

      Affiliations

    • Corresponding Author InformationOffprint requests to: Angel F. Lopez, M.D., Ph.D., Division of Human Immunology, IMVS, Adelaide, SA 5000, Australia
    • Cytokine Receptor Laboratory, Division of Human Immunology, IMVS, Adelaide, South Australia

Received 15 April 2002 ,Revised 14 June 2002 ,Accepted 20 June 2002.

References 

  1. Cambier N, Baruchel A, Schlageter MH, et al.  Chronic myelomonocytic leukemia (from biology to therapy). Hematol Cell Ther. 1997;39:41
  2. Seymour JF, Cortes JE. Chronic myelomonocytic leukemia. In:  Talpaz M,  Kantarjian HM editor. Medical management of chronic myelogenous leukemia. New York: Marcel Dekker Inc; 1998; 43p
  3. Onida F, Kantarjian HM, Smith TL, et al.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia (a retrospective analysis of 213 patients). Blood. 2002;99:840
  4. Harris NL, Jaffe ES, Diebold J, et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues (report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997). J Clin Oncol. 1999;17:3835
  5. Beran M, Kantarjian H. Topotecan in the treatment of hematologic malignancies. Sem Hematol. 1998;35(suppl. 4):26
  6. Saba HI. Myelodysplastic syndromes in the elderly (the role of growth factors in management). Leuk Res. 1996;20:203
  7. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica. 1998;83:910
  8. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343
  9. Parker J, Mufti GJ. Ras and myelodysplasia (lessons from the last decade). Sem Hematol. 1996;33:206
  10. Kuno Y, Abe A, Emi N, et al.  Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12) (q22;p12). Blood. 2001;97:1050
  11. Schwaller J, Frantsve J, Aster J, et al.  Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17:5321
  12. Ritchie KA, Aprikyan AA, Bowen-Pope DF, et al.  The Tel-PDGFRβ fusion gene produces a chronic myeloproliferative syndrome in transgenic mice. Leukemia. 1999;13:1790
  13. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307
  14. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor b receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFbR kinase-dependent signaling pathways. Proc Natl Acad Sci U S A. 1996;93:14845
  15. Tomasson MH, Williams IR, Hasserjian R, et al.  TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood. 1999;93:1707
  16. Yanagisawa K, Hatta N, Watanabe I, Horiuchi T, Hasegawa H, Fujita S. IL-4 stimulates the growth of chronic myelomonocytic leukemia cells (CMMoL) once leukemic transformation has occurred. Leukemia. 1995;9:1056
  17. Geissler K, Ohler L, Födinger M, et al.  Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. J Exp Med. 1996;184:1377
  18. Oehler L, Foedinger M, Koeller M, et al.  Interleukin-10 inhibits spontaneous colony-forming unit growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release. Blood. 1997;89:1147
  19. Herold M, Schmalzl F, Zwierzina H. Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. Leuk Res. 1992;16:585
  20. Everson MP, Brown CB, Lilly MB. Interleukin-6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells. Blood. 1989;74:1472
  21. Shultz LD, Schweitzer PA, Christianson SW, et al.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154:180
  22. Lewis ID, McDiarmid LA, Samels LM, To LB, Hughes TP. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood. 1998;91:630
  23. Rebouissou C, Wijdenes J, Autissier P, et al.  A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood. 1998;91:4727
  24. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730
  25. Iversen PO, Lewis ID, Turczynowicz S, et al.  Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood. 1997;90:4910
  26. Hercus TR, Bagley CJ, Cambareri B, et al.  Specific human granulocyte-macrophage colony-stimulating factor antagonists. Proc Natl Acad Sci U S A. 1994;91:5838
  27. Barry SC, Bagley CJ, Phillips J, et al. (1994) Two contiguous residues in human interleukin-3, Asp21 and Glu22, selectively interact with the α- and β-chains of its receptor and participate in function. J
  28. Hogan B, Beddington R, Constantini F, Lacy E (1994) Manipulating the Mouse Embryo. A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press, p. 217
  29. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156
  30. Frohman MA, Dush MK, Martin GR. Rapid production of full-length cDNAs from rare transcripts (amplification using a single gene-specific oligonucleotide primer). Proc Natl Acad Sci U S A. 1988;85:8998
  31. Sun Q, Woodcock JM, Rapoport A, et al.  Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor α-chain and functions as a specific IL-3 receptor antagonist. Blood. 1996;87:83
  32. Iversen PO, To LB, Lopez AF. Apoptosis of hemopoietic cells by the human granulocyte-macrophage colony-stimulating factor mutant E21R. Proc Natl Acad Sci U S A. 1996;93:2785
  33. Zwierzina H, Schollenberger S, Herold M, Schmalzl F, Besemer J. Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes. Leuk Res. 1992;16:1181
  34. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77:925
  35. Iversen PO, Rodwell RL, Pitcher L, Taylor KM, Lopez AF. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R. Blood. 1996;88:2634
  36. Birnbaum RA, O'Marcaigh A, Wardak Z, et al.  Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000;5:189
  37. Bernard F, Thomas C, Emile JF, et al.  Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood. 2002;99:2615
  38. Tomasson MH, Williams IR, Li S, et al.  Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3. Blood. 2001;97:1435
  39. Bock TA, Orlic D, Dunbar CE, Broxmeyer HE, Bodine DM. Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes. J Exp Med. 1995;182:2037
  40. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse (murine model for the analysis of human hematolymphoid differentiation and function). Science. 1988;241:1632
  41. Dick JE. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol. 1996;8:197
  42. Wang JCY, Lapidot T, Cashman JD, et al.  High level engraftment of NOD/SCID mice by primitive normal and leukaemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998;91:2406
  43. Ramshaw HS, Lopez A, Bardy P. The development of cytokine receptor antagonists as potential therapeutic agents for the myeloproliferative disorders. Curr Pharm Des. 2002;8:125
  44. Frankel AC, Lilly M, Kreitman RJ, et al.  Diptheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood. 1998;92:4279
  45. O'Brien P, Smythe A, Biggs JC, Smith GM. A recombinant GM-CSF–PE40 ligand toxin is functionally active but not cytotoxic to cells. Immunol Cell Biol. 1997;75:289

PII: S0301-472X(02)00903-7

Experimental Hematology
Volume 30, Issue 10 , Pages 1124-1131 , October 2002

Article Tools

* Image Usage & Resolution